Loading data for AVTX — first visit, this takes a few seconds.

Alerta

Avalo Therapeutics Inc. (AVTX)

NasdaqCM: AVTX · Precio en tiempo real · USD

19.82

-0.93 (-4.48%)

Al cierre: Aug 20, 2026, 8:00 PM

19.52

-1.51%

Fuera de horario: 7:30 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-4.48% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	1.06B
Ingresos (TTM)	59K
Beneficio neto (TTM)	-100.33M
	0.79
	-4.21
	n/a
	-7.53
P/B (TTM)	2.34
P/S (TTM)	18016.04
Fecha de resultados	Nov 12, 2026

Precio de venta	n/a
Volumen	698,454
Volumen medio (20D)	1,348,079
Abierto	20.38
Anterior Cerrar	20.75
Rango del día	19.49 - 20.57
Rango de 52 semanas	8.65 - 24.27
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Thera...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Oct 14, 2015

Empleados 33

Bolsa de Valores NasdaqCM

Símbolo bursátil AVTX

Sitio web https://www.avalotx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Avalo Therapeutics fueron 59K, una disminución de -86.62% en comparación con 441K del año anterior. Las ganancias fueron -78.26M, un aumento de 122.78%.

Estados financieros

Sorpresa de resultados

Avalo Therapeutics ha publicado sus resultados trimestrales en Aug 6, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.83 falla las estimaciones por -0.21, con 56.77% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Avalo Therapeutics Inc. publique sus resultados el Nov 12, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Simply Wall St.

Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?

Avalo Therapeutics, Inc. reported past earnings for the second quarter and first half of 2026, with net losses of US$36.36 million and US$55.99 million respectively, both higher than the same periods ...

1 mes hace · Simply Wall St.

Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed

Avalo Therapeutics was recently added to a broad range of Russell indices, including the Russell 2000, 2500, 3000 and related growth, value and small-cap benchmarks, following index reconstitutions co...

1 mes hace · Insider Monkey

Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best low priced stocks to get rich in 2026. On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a pric...

2 meses hace · MT Newswires

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State St

3 meses hace · Investor's Business Daily

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.

Página 1 de 2

Avalo Therapeutics Inc. (AVTX)